Artificial Intelligence (AI) for De Novo Drug Design Global Market Report 2026 | Secure 33.7% CAGR Through 2030 with Schrödinger, XtalPi, Owkin, Insilico Medicine and Recursion
Dublin, Oct. 27, 2026 (GLOBE NEWSWIRE) -- "AI for De Novo Drug Design Global Market Report 2026" has been added to ResearchAndMarkets.com's offering.
The global artificial intelligence (AI) for de novo drug design market is experiencing exponential growth as pharmaceutical and biotechnology organizations adopt advanced computational technologies to accelerate drug discovery. The market is projected to increase from $1.9 billion in 2025 to $2.53 billion in 2026, representing a compound annual growth rate (CAGR) of 33.4%.
Historic market growth has been supported by the high research and development costs associated with traditional drug discovery, rising demand for shorter development timelines, broader adoption of computational chemistry tools, increased pharmaceutical investment, and expanding collaboration among academic institutions, research organizations, and industry participants.
The AI for de novo drug design market is forecast to reach $8.07 billion by 2030, expanding at a CAGR of 33.7%. Growth during the forecast period is expected to be driven by wider adoption of AI-powered lead compound generation, increasing use of absorption, distribution, metabolism, excretion, and toxicity prediction models, and greater integration of cloud-based and on-premises technologies. Investment in model development, data annotation services, and partnerships between pharmaceutical and biotechnology companies will also support market expansion.
Key AI drug discovery market trends include the growing use of cloud-based AI platforms, rising demand for deep learning drug design software, and greater implementation of workflow automation. Molecular property prediction tools are becoming increasingly important as researchers seek to evaluate potential compounds earlier in the discovery process. Companies are also placing greater emphasis on targeted therapeutic applications, including oncology, neurological disorders, infectious diseases, cardiovascular conditions, rare diseases, and metabolic disorders.
The increasing prevalence of complex diseases is a major factor driving demand for AI-assisted de novo drug design. Unhealthy lifestyle patterns, aging populations, and the growing burden of chronic conditions are increasing the need for innovative therapies. AI technologies can process extensive biological and chemical datasets, identify relevant patterns, and predict promising drug candidates, helping researchers address multifactorial diseases and difficult therapeutic targets.
According to the World Health Organization, more than 35 million new cancer cases are expected worldwide in 2050. This would represent a 77% increase from the estimated 20 million cases recorded in 2022. The projected rise in cancer incidence highlights the need for more efficient drug discovery strategies and is expected to strengthen demand for AI-enabled molecular generation, predictive modeling, lead optimization, and candidate selection.
Innovation remains central to the competitive development of the artificial intelligence for de novo drug design market. In November 2025, Terray Therapeutics launched EMMI, an AI-native drug discovery platform engineered for de novo small-molecule design. The platform combines ultra-miniaturized experimental hardware, an automated laboratory environment, and the company's third-generation Chemistry-Oriented AI Transformer Interface model.
EMMI is designed to generate millions of novel molecules, predict potency, identify promising candidates, and iteratively optimize molecular structures. Its generative AI capabilities use reinforcement learning to propose synthetically accessible molecules, while predictive models assess characteristics including potency, selectivity, solubility, metabolism, and clearance. Selection AI then determines which molecules should move into synthesis. Terray Therapeutics states that this integrated process can reduce drug discovery time and costs by up to threefold compared with industry standards. The technology supports internal immunology programs and strategic research partnerships exploring previously unaddressed areas of chemical space.
Strategic acquisitions are also strengthening AI drug discovery capabilities. In July 2023, BioNTech SE completed its acquisition of InstaDeep Ltd. for $549 million (€500 million). The transaction was intended to expand BioNTech's artificial intelligence and machine learning capabilities across drug discovery and development. By integrating InstaDeep's technology, BioNTech aims to accelerate the development of next-generation immunotherapies and vaccines while strengthening its broader computational research infrastructure.
North America was the largest regional market for artificial intelligence in de novo drug design in 2025, supported by advanced pharmaceutical research, technology investment, established biotechnology clusters, and strong adoption of AI-enabled discovery platforms. Asia-Pacific is expected to be the fastest-growing region during the forecast period. The market analysis covers Asia-Pacific, Southeast Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. Countries covered include Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, the United Kingdom, the United States, Canada, Italy, and Spain.
Markets Covered:
1) By Component: Software; Services
2) By Therapeutic Area: Oncology; Neurological Disorders; Infectious Diseases; Cardiovascular Diseases; Rare Diseases; Metabolic Disorders; Other Therapeutic Areas
3) By Deployment Mode: On-Premises; Cloud-Based
4) By Application: Target Identification; Lead Compound Generation; Molecular Property Prediction; Absorption, Distribution, Metabolism, Excretion, And Toxicity (ADMET Prediction); Other Applications
5) By End User: Pharmaceutical Companies; Biotechnology Companies; Academic and Research Institutes; Contract Research Organizations; Other End Users
Subsegments:
1) By Software: Cloud Based Software; On Premise Software; Machine Learning Software; Deep Learning Software; Molecular Modeling Software; Data Analytics Software; Workflow Automation Software
2) By Services: Consulting Services; Integration Services; Maintenance and Support Services; Training and Education Services; Managed Services; Data Annotation Services; Model Development Services
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Key Attributes:
Companies Featured
The companies featured in this AI for De Novo Drug Design market report include:
For more information about this report visit https://www.researchandmarkets.com/r/i3ptqy
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.